Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 6, 2010

Pfizer Obtains Pan-EU Approval for Lipitor in Patients Aged 10–17 Years

Pfizer Obtains Pan-EU Approval for Lipitor in Patients Aged 10–17 Years

Firm aims to apply for six-month patent extension to existing SPC in relevant European countries.

  • The European regulatory authorities have approved a chewable formulation of Pfizer’s Lipitor for the treatment of familial hypercholesterolemia in children aged 10-17 years. The pediatric indication has also been sanctioned for the currently available tablet form of Lipitor. Approval of the drug for this younger patient population is based on data from a pediatric investigation plan Pfizer filed with the European Medicines Agency in November 2009.

    The firm says the EU has created a number of incentives to help persuade companies to invest in clinical development of drugs for use in children. These incentives include the potential to prolong patent life by another six months by applying for an extension to an existing supplementary protection certificate (SPC). Pfizer confirmed it plans to apply for the six-month patent extension in European countries where it has an SPC.

    Lipitor has been approved in the U.S. for treating heterozygous familial hypercholesterolemia in children aged 10-17 years since 2002.


Readers' Comments

Posted 07/06/2010 by Tom Hennessy

Vegetable lecithin has been shown to be as effective as Lipitor in lowering of cholesterol. 
Lecithin works so well just placing it on the skin is shown to lower cholesterol.
No doctors should be ALLOWED to prescribe cholesterol lowering drugs used UNTIL the non-synthetic natural vegetable lecithin has been proven to NOT work.
Imho ..
"One of the more unusual presentations described how lecithin applied topically to the skin decreased blood cholesterol in people with normal and high blood cholesterol levels."


Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »